




Patient-rated changes in fatigue over a 12-month period predict poor outcome in heart
failure
Smith, O.R.F.; Denollet, J.; Schiffer, A.A.J.; Kupper, N.; Gidron, Y.Y.
Published in:






Publisher's PDF, also known as Version of record
Link to publication in Tilburg University Research Portal
Citation for published version (APA):
Smith, O. R. F., Denollet, J., Schiffer, A. A. J., Kupper, N., & Gidron, Y. Y. (2009). Patient-rated changes in
fatigue over a 12-month period predict poor outcome in heart failure. European Journal of Heart Failure, 11(4),
400-405. https://doi.org/10.1093/eurjhf/hfp002
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 12. May. 2021
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patient-rated changes in fatigue over a 12-month
period predict poor outcome in chronic
heart failure
Otto R.F. Smith1, Johan Denollet1*, Angélique A. Schiffer1,2, Nina Kupper1, and
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Aims Little is known about the factors that are associated with changes in fatigue in chronic heart failure (CHF). Moreover,
it is unclear whether these changes have prognostic impact. The aim of this study was to examine these issues.
Methods
and results
Three hundred and eighty-seven CHF patients were assessed twice (at baseline and at 12-month follow-up) for exer-
tion and general fatigue. Regression models were developed to assess whether baseline characteristics predicted
changes in fatigue and to assess the effect of changes in fatigue on cardiac events occurring beyond 12-months of
follow-up. An increase in exertion fatigue over a 12-month period was predicted by higher left ventricular ejection
fraction (P ¼ 0.02) and cognitive-affective depressive symptoms (P ¼ 0.03) at baseline, and not having a biventricular
pacemaker shortly after baseline (P ¼ 0.02), whereas an increase in general fatigue was only predicted by cognitive-
affective depressive symptoms (P ¼ 0.002). One hundred and forty-three patients (37%) experienced an event (read-
mitted, 117; death, 26). An increase in exertion fatigue was associated with a near two-fold increased risk of events
beyond 12-months of follow-up (hazard ratio ¼ 1.78; 95% confidence interval 1.18–2.68, P ¼ 0.006), while control-
ling for standard cardiac risk factors.
Conclusion Baseline clinical and psychosocial factors predicted changes in fatigue. Increased exertion fatigue independently pre-
dicted an increased risk of cardiac re-admission or death.
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Introduction
Fatigue is commonly reported by chronically ill patients.1 – 3 In
chronic heart failure (CHF), fatigue is one of the most prevalent
and distressing symptoms, which is also associated with disease
progression.4– 7 Nevertheless, research concerning the clinical rel-
evance of self-reported fatigue in CHF is underreported in the car-
diovascular literature, which may partially be due to its ambiguous
nature.
Explaining fatigue in CHF has proven to be difficult.6,8 Previous
studies have shown that left ventricular function measures relate
poorly to fatigue.9,10 Fatigue may be due to impaired skeletal
muscle blood supply as a result of reduced cardiac output.11
Recently, it has been suggested that chronic, low grade haemo-
dynamic stress, as seen in CHF, may lead to dominance of catabolic
processes. This in turn leads to skeletal myopathy, causing the sen-
sation of fatigue.11,12 However, it remains unclear to what extent
these factors may fully explain individual differences in fatigue.
Previous studies have demonstrated patients’ self-assessment of
CHF symptoms to be independently associated with poor progno-
sis.13,14 In addition, it has been shown that self-assessed symptoms
and New York Heart Association (NYHA) classification are not
coherent,13 indicating that there is little agreement between
patient- and physician-rated CHF symptoms. Self-assessed fatigue
may therefore provide useful additional information about the
patients’ clinical and prognostic status.
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The dynamic nature of symptoms, in general, and fatigue, in par-
ticular, makes it necessary to examine these symptoms prospec-
tively over time. Efforts should be made to gain knowledge
about subgroups of CHF patients who are at increased risk of
developing worse fatigue status over time, thereby providing an
opportunity for risk stratification and prevention. Moreover, the
prognostic impact of changes in self-reported fatigue should be
examined as well.
The aims of this study were: (i) to determine clinical, demo-
graphic, and psychological predictors of changes in fatigue over a
12-month period and (ii) to examine whether these changes in
fatigue were predictive of adverse cardiac events occurring
beyond 12 months in patients with systolic CHF.
Methods
Patients
Patients attending the heart failure outpatient clinic of the TweeSteden
Hospital, Tilburg, the Netherlands, were eligible to participate in the
study. Inclusion criteria were defined as systolic heart failure, left ven-
tricular ejection fraction (LVEF) 40%, and sufficient understanding of
spoken and written Dutch language. Exclusion criteria were defined as
diastolic heart failure, age 80 years, myocardial infarction in the
month prior to inclusion, and other life-threatening diseases.
Patients completed a questionnaire at baseline and at the 12-month
follow-up. Information about cardiac re-admission or death was col-
lected beyond the 12-month follow-up. The overall design of the
study is shown in Figure 1. The hospital’s medical Ethics Committee
approved the study protocol, and the study was carried out according
to the Helsinki Declaration. All patients provided written informed
consent.
Changes in fatigue
Previous research has suggested how to differentiate between exertion
and general fatigue. The former refers to fatigue directly related to per-
forming of activities in daily living,15 whereas the latter refers to an
overwhelming, sustained sense of exhaustion that does not necessarily
have a relationship with exertion.16 The Dutch Exertion Fatigue Scale
(DEFS) assesses exertion fatigue by means of nine items.15 Items are
answered with five response alternatives, ranging from 0 (no) to 4
(yes). Cronbach’s alpha was good in the present study (a ¼ 0.91).
The Fatigue Assessment Scale (FAS) was used to assess general
fatigue.17 This questionnaire consists of 10 items, which are answered
on a 5-point Likert scale, ranging from 1 (never) to 5 (always). In the
present study, the reliability of this instrument was high (a ¼ 0.90).
Changes in exertion and general fatigue were calculated by means of
residualized change scores (Dexertion fatigueres and Dgeneral
fatigueres). These changed measures reflect the degree to which an
individual increased or decreased more than would be expected
given his or her initial status. Residualized change scores are preferable
to simple change scores because they eliminate autocorrelated error
and regression to the mean effects.18
Clinical events beyond 12-month follow-up
Patients’ hospital medical records were used to assess whether
patients had been re-admitted for cardiovascular causes since the
12-month follow-up. The same procedure was followed to assess mor-
tality. Accordingly, the combined clinical endpoint was defined as
cardiac hospital re-admission or death. The mean duration of follow-up
counting from 12 months after baseline was 782 days (range 1–1798).
Clinical correlates
Clinical variables included LVEF, NYHA class, aetiology of CHF, cardiac
history, biventricular pacemaker status, smoking status, body mass
index (BMI), 6 min walking test, physical inactivity, co morbidities,
and medication. Information on clinical variables was obtained from
the patients’ medical records and from the treating cardiologist. Socio-
demographic information included sex, age, marital status, and edu-
cational level.
Symptoms of dyspnoea
As dyspnoea is one of the core symptoms of CHF, it was included as a
potential predictor of changes in fatigue. Symptoms of dyspnoea were
measured by a subscale of the Health Complaint Scale.19 Items are
answered on a 5-point Likert scale, ranging from 0 (not at all) to 4
(extremely).
Symptoms of depression
Symptoms of depression were assessed by means of the Beck
Depression Inventory (BDI).20 Each item is rated on a 0–3 scale.
The BDI is a reliable and well-validated measure of depressive sympto-
matology21,22 and is the most widely used self-reported measure of
depression. As the somatic items of the BDI may be confounded by
fatigue, only the cognitive-affective subscale was used.23
Type-D personality
Personality was also used as a potential determinant of changes in
fatigue. Type D personality was assessed by means of the 14-item
type D scale, which comprises two subscales: negative affectivity and
social inhibition.24 A standardized cut-off score 10 on both subscales
classifies individuals as having a type D personality. Both scales have
good internal reliability (a ¼ 0.88 and 0.86, respectively) and are
stable over time.24,25
Statistical analyses
Prior to statistical analyses, educational level, marital status, NYHA
class, aetiology of heart failure, co-morbidities, and cardiac history
were recoded into dichotomous variables. At 12 months of follow-up,
19.4% of the DEFS scores and 19.1% of the FAS scores were missing.
Simply excluding these patients wastes potential information and could
bias results. Therefore, SAS procedure multiple imputation was used
to create ten data sets to estimate values for missing data. After ordin-
ary analysis, SAS procedure MIANALYZE was used to combine the
results of the ten data sets.26,27
SAS procedure REG was used to determine predictors of changes in
fatigue. All baseline variables were forced into a multivariable model
predicting, respectively, changes in exertion fatigue and general
fatigue. Cox proportional hazards regression, by means of the SAS
procedure PHREG, was used to assess whether changes in fatigue
Figure 1 Design of the study.
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predicted the combined endpoint of cardiovascular re-admission or
death beyond the 12 month follow-up. In multivariable analysis, we
included standard cardiac risk factors (age, sex, smoking, BMI, physical
inactivity, hypertension, hypercholesterolaemia, and diabetes),
measures of disease severity (LVEF and NYHA class), and variables
that predicted changes in fatigue.
Results
Baseline characteristics
Of the original 419 patients included in the study, 32 were
excluded from the final analysis because they died between base-
line and 12-month follow-up; hence, changes in fatigue could not
be assessed. Patients who completed the study differed systemati-
cally from those who died within 12 months after baseline. Patients
who died were more likely to be older (t ¼ 2.76, df ¼ 419;
P ¼ 0.006), male (x2 ¼ 4.31, df ¼ 1; P ¼ 0.04), physically inactive
(x2 ¼ 4.06, df ¼ 1; P ¼ 0.04), and were more likely to be in
NYHA class III/IV (x2 ¼ 6.02, df ¼ 1; P ¼ 0.01). In addition, they
had lower ejection fraction (t ¼ 22.83, df ¼ 404; P ¼ 0.005) and
lower exercise capacity (t ¼ 24.11, df ¼ 413; P , 0.001). Baseline
levels of both exertion (t ¼ 3.18, df ¼ 415; P ¼ 0.002) and general
fatigue (t ¼ 2.14, df ¼ 413; P ¼ 0.03) were significantly higher in
patients who died between baseline and 12 months of follow-up
when compared with patients who completed the study. Baseline
characteristics of the 387 patients included in the final analysis are
displayed in Table 1. The mean age of patients was 66.4 years,
70.3% were male, and 42.9% were in NYHA class III/IV.
Predictors of changes in fatigue
Multiple regression analysis revealed that changes in exertion fatigue
over a 12-month period were predicted by LVEF, implantation
of a biventricular pacemaker (BVP), beta-blockers, and cognitive-
affective depressive symptoms. Patients having a higher LVEF,
having more cognitive-affective depressive symptoms, not having a
BVP, and not using beta-blockers were more likely to have an
increase in exertion fatigue at the 12-month follow-up. Changes in
general fatigue were only predicted by cognitive-affective depressive
symptoms. Patients with higher levels of depressive symptoms
showed a greater increase in general fatigue at the 12-month
follow-up when compared with those with lower levels of depress-
ive symptoms (Table 2).
Changes in fatigue and hospital
re-admission/death
As indicated before, the composite endpoint was defined as
cardiac hospital re-admission or death that occurred beyond the
12-month follow-up assessment of fatigue. The mean duration of
follow-up counting from 12 months after baseline was 782 days
(range 1–1798). Over the period of follow-up, 143 patients
(37%) experienced an event (re-admitted, 117 and death, 26).
In univariable analysis, an increase in both general fatigue [hazard
ratio (HR) ¼ 1.04, 95% confidence interval (CI) 1.00–1.07;
P ¼ 0.03] and exertion fatigue (HR ¼ 1.04, 95% CI 1.01–1.07;
P ¼ 0.005) were associated with an increased risk of cardiovascular
re-admission or death. In multivariable analysis, we controlled for
the variables listed in Table 3. Accordingly, increased exertion
fatigue was an independent predictor of cardiovascular re-admission
or death (HR ¼ 1.04, 95% CI 1.00–1.07; P ¼ 0.03). Smoking
(HR ¼ 1.58, 95% CI 1.08–2.32; P ¼ 0.02), BMI (HR ¼ 1.01, 95%
CI 1.00–1.02; P ¼ 0.04), and diabetes (HR ¼ 1.61, 95% CI
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .




Implementation of BVP 20.14 0.03
Beta-blocker 20.11 0.05
Cognitive-affective depressive symptoms 0.17 0.02
General fatigue
Implementation of BVP 20.12 0.09
Statins 20.13 0.07
Cognitive-affective depressive symptoms 0.20 0.002
aOnly variables with P , 0.10 are reported.
BVP, biventricular pacemaker; LVEF, left ventricular ejection fraction.
Table 1 Baseline characteristics (n 5 387)
Age (SD) 66.4 (10.7)
Male, % (n) 70.3 (272)
Low educational level, % (n) 33.3 (129)
Having a partner, % (n) 70.8 (274)
Smoking, % (n) 23.0 (89)
Body mass index (SD) 28.6 (12.0)
Physical inactivity, % (n) 44.2 (171)
LVEF (SD) 30.7 (6.8)
NYHA class III/IV, % (n) 42.9 (166)
Ischaemic aetiology, % (n) 54.5 (211)
Hypertension, % (n) 39.8 (154)
Hypercholesterolaemia, % (n) 47.5 (184)
Diabetes, % (n) 23.8 (92)
Co-morbidity, % (n)a 38.0 (147)
Implementation of BVP, % (n)b 9.3 (36)
Cardiac history, % (n)c 57.4 (222)
ACE inhibitors, % (n) 73.1 (283)
Diuretics, % (n) 72.6 (281)
Beta-blockers, % (n) 66.9 (259)
Statins, % (n) 49.9 (193)
Aspirin, % (n) 42.9 (166)
Psychotropic medication, % (n) 13.2 (51)
6 min walking test (SD) 276.3 (159.6)
Symptoms of dyspnoea (SD) 2.4 (2.2)
Cognitive-affective depressive symptoms (SD) 1.3 (2.8)
Type-D personality, % (n) 19.6 (76)
aStroke, chronic obstructive pulmonary disease, peripheral arterial disease, liver
disease, and renal insufficiency.
bImplementation of a biventricular pacemaker shortly after baseline.
cHistory of MI, CABG, and PCI.
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1.09–2.36; P ¼ 0.02) also predicted cardiovascular re-admission or
death. General fatigue did not predict clinical events in the multi-
variable analysis (Table 3).
Next,Dexertion fatigueres was dichotomized using the highest quin-
tile (Dexertion fatigueres , 5 ¼ 0 and Dexertion fatigueres  5 ¼ 1).
Accordingly, the event rate was 34% (n ¼ 104) in the non-increased
exertion fatigue group and 46% (n ¼ 39) in the increased exertion
fatigue group. The Kaplan–Meier curve in Figure 2 shows that
patients in the increased exertion fatigue group were more likely
to experience an event when compared with those in the non-
increased exertion fatigue group (P ¼ 0.01). Multivariable analysis
revealed that patients in the increased exertion fatigue group had
a near two-fold increased risk of experiencing an adverse event
(HR ¼ 1.78, 95% CI 1.18–2.68; P ¼ 0.006).
Discussion
To the best of our knowledge, this is the first study to examine the
predictors of changes in fatigue over time in CHF patients and to
examine the prognostic impact of these changes in fatigue. An
increase in exertion fatigue over a 12-month period was predicted
by higher LVEF and cognitive-affective depressive symptoms at
baseline, and by not having a BVP implanted shortly after baseline.
An increase in general fatigue was only predicted by cognitive-
affective depressive symptoms.
Increased exertion fatigue at 12 months of follow-up was inde-
pendently associated with an increased risk of cardiovascular
re-admission or death beyond the 12-month follow-up, whereas
an increase in general fatigue was only associated with adverse out-
comes in the univariable analysis. These results are in line with the
studies, which show that fatigue in CHF7,13,14 and increased fatigue
in coronary patients28 are associated with adverse outcomes.
Fatigue is considered to be one of the most important factors
affecting patients quality of life, and there is a growing need for ade-
quate clinical management of fatigue.29,30 However, little is known
about why patients experience fatigue,31 and explaining individual
differences in fatigue has proven to be difficult.6 The current
study identified factors that contribute to change in fatigue over
time in CHF patients. In accordance with the previous work,32
implantation of a BVP was associated with a decrease in exertion
fatigue. Changes in both exertion and general fatigue were pre-
dicted by cognitive-affective depressive symptoms at baseline.
This result extends our previous findings8 and lends further
support to the possible role of depression in the perception and
reporting of disease-specific symptoms in CHF.8 The association
between higher LVEF and increased exertion fatigue was counter-
intuitive, but it could be that better status on both LVEF and exer-
tion fatigue at baseline is more likely to deteriorate than if either or
both are already significantly impaired.
The current study emphasizes the importance of recognizing
changes in fatigue in clinical practice. Recognition of these
changes allows healthcare professionals to act on this, for
example, by offering exercise training. The importance of exercise
training was recently reviewed in a meta-analysis by Puetz et al.,33
in which they showed that cardiac rehabilitation exercise pro-
grammes have considerable effects on levels of energy and
fatigue. However, it remains unclear whether improvement after
therapy is associated with improved prognosis. Future studies
should address this issue.
In addition, the mechanisms through which fatigue exerts its
negative effects are unclear. We hypothesize that mechanisms
are different for exertion and general fatigue. Exertion fatigue
may primarily reflect the direct physical consequences of the
disease itself, and an increase in exertion fatigue may therefore
reflect worsening of CHF. Future studies should assess physiologi-
cal measures that are known to be abnormal in CHF patients
and that are relevant with respect to fatigue, for example,
measures of abnormal muscle metabolism and an enhanced ergo
Figure 2 Event-free survival rate of cardiovascular re-admission
or death according to increases in exertion fatigue.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Multivariable predictors of cardiovascular
re-admission or death
Variable HR 95% CI P-value
Age (SD) 1.00 0.98–1.01 0.72
Male 1.46 0.97–2.21 0.07
Hypertension 0.82 0.58–1.17 0.28
Hypercholesterolaemia 0.99 0.68–1.45 0.97
Smoking 1.58 1.08–2.32 0.02
Body mass index 1.01 1.00–1.02 0.04
Physical inactivity 1.16 0.82–1.65 0.40
Diabetes 1.61 1.09–2.36 0.02
LVEF (SD) 0.99 0.97–1.02 0.49
NYHA class III/IV 1.37 0.95–1.96 0.09
Statins 1.17 0.80–1.73 0.42
Beta-blocker 0.92 0.64–1.33 0.67




DGeneral fatigueres 1.01 0.97–1.05 0.59
DExertion fatigueres 1.04 1.00–1.07 0.03
BVP, biventricular pacemaker; LVEF, left ventricular ejection fraction.
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reflex response.11,12 Future studies should measure changes in
exertion fatigue and these physiological parameters in parallel. In
contrast, general fatigue may reflect more psychological conse-
quences of CHF and may, to some extent, be on a par with
mental fatigue. A hint towards this association was given by the
fact that the increase in general fatigue was predicted only by
cognitive-affective depressive symptoms. Increased general fatigue
may therefore have an impact on the patients’ ability for self-care,
which has been associated with poor prognosis in CHF.34
There is also some evidence that vital exhaustion, a concept
related to general fatigue, is associated with increased levels of
inflammatory markers in patients with coronary heart
disease.35,36 These cytokines have been associated with adverse
outcomes in CHF.37– 39 Indeed, one important sign of peripheral
inflammatory signals is fatigue and behavioural withdrawal,40 as
part of the sickness response. Further research into the mechan-
isms responsible for the link between fatigue and CHF prognosis
is warranted in order to optimize treatment strategies. Given the
failure of anti-tumour necrosis factor medication to improve prog-
nosis in CHF41 and if increases in fatigue are found to be related to
proinflammatory cytokines, such interventions may be more effec-
tive if provided specifically to patients with worse fatigue.
This study had a number of limitations. First, there may have
been a bias in the selection of patients. The cardiologist or heart
failure nurses asked patients to participate in the study, and this
interaction pattern might have influenced selection. Secondly, we
used combined endpoints in order to increase the number of clini-
cal events and did not use mortality as a separate endpoint. Factors
predicting re-admission may differ from those predicting death.
Thirdly, we did not have data available on changes in variables
other than fatigue. For future studies, it would be interesting to
determine whether changes in cardiac function, renal function,
6 min walk test, or peak oxygen consumption are related to
changes in fatigue. Fourth, we did not have information on diagno-
sis of major depression. Nevertheless, the strengths of the current
study were the repeated assessment of fatigue over time and the
prospective design examining the impact of these changes in
fatigue on prognosis. Finally, we used reliable and valid measures
of both exertion and general fatigue.
In summary, changes in fatigue were related to clinical and psy-
chosocial factors, and increased exertion fatigue independently
predicted an increased risk of cardiac re-admission or death. The
current study contributes to the understanding of fatigue in CHF
and reveals that changes in fatigue are of clinical and prognostic
importance. Taking symptom changes into account, in addition
to their biomedical and psychosocial predictors, may lead
to improved risk stratification and clinical management in this
high-risk patient group.
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